Evolus’ (EOLS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note released on Tuesday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. Finally, Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Trading Up 1.1%

Evolus stock opened at $8.88 on Tuesday. Evolus has a 1-year low of $3.86 and a 1-year high of $9.12. The firm has a market capitalization of $586.52 million, a price-to-earnings ratio of -17.08 and a beta of 1.35. The firm’s fifty day moving average price is $7.00 and its two-hundred day moving average price is $5.89.

Institutional Investors Weigh In On Evolus

Hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its position in shares of Evolus by 79.9% in the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock valued at $38,000 after purchasing an additional 2,423 shares in the last quarter. Angeles Wealth Management LLC purchased a new stake in Evolus during the 2nd quarter worth about $732,000. Concurrent Investment Advisors LLC purchased a new stake in Evolus during the 2nd quarter worth about $193,000. Braidwell LP lifted its holdings in Evolus by 1.6% during the 2nd quarter. Braidwell LP now owns 3,155,209 shares of the company’s stock worth $21,897,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in Evolus in the 2nd quarter worth about $1,179,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.